| Name | Title | Contact Details |
|---|---|---|
John Meulen |
Vice President, Sales for Specialty Solutions S H | Profile |
Kevin Howat |
Vice President, Direct Health Care Sales S H | Profile |
John Vander Meulen |
Vice President of Sales-Specialty Solu... | Profile |
LENSAR, Inc. is a global leader in next-generation femtosecond laser technology for refractive cataract surgery. The LENSAR Laser System offers cataract surgeons precision, accuracy, and efficiency while optimizing overall visual outcomes. LENSAR`s proprietary Augmented Reality technology -- reconstructed 3-D imaging, measurement, and guidance system -- offers quick and easy patient docking and provides high-resolution ocular images in a single scan. This technology facilitates enhanced procedure outcomes by allowing the physician to develop individualized treatment plans including precise laser delivery, and efficient lens fragmentation that can reduce, and potentially eliminate phaco energy. The LENSAR Laser System also offers the industry`s smallest laser footprint and thoughtful ergonomic design that accommodates most operating rooms. The LENSAR Laser System has been cleared by FDA for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. For other indications it is an investigational device limited by U.S. law to investigational use only
Mini Pharmacy Diabetes Supplies is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Health Care Supply Company is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chase Ergonomics Inc. is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.